Vaupel Peter, Dunst Jürgen, Engert Andreas, Fandrey Joachim, Feyer Petra, Freund Mathias, Jelkmann Wolfgang
Institut für Physiologie und Pathophysiologie, Universität Mainz, Germany.
Onkologie. 2005 Apr;28(4):216-21. doi: 10.1159/000084033. Epub 2005 Mar 31.
It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).
众所周知，贫血诱导的肿瘤缺氧与肿瘤对放疗和某些化疗形式的敏感性降低有关。因此，用重组人促红细胞生成素（rHuEPO）纠正较低的血红蛋白（Hb）浓度可通过改善肿瘤氧合发挥重要作用。基于多项试验的证据，rHuEPO治疗将有效改善贫血并提高生活质量。然而，实现这一益处的最重要前提之一是按照基于证据的美国临床肿瘤学会/美国血液学会指南使用rHuEPO，该指南建议目标Hb浓度为12 g/dl（7.44 mmol/l）。
